Difference between revisions of "ERF for short term PM10 exposure and medication usage by people with asthma"

From Testiwiki
Jump to: navigation, search
(New page: {{variable|moderator = Virpi Kollanus}} Category: CLAIH Category: PM exposure health effects '''Boxes with dashed borders''' contain brief guidance text for completing the entri...)
 
 
(One intermediate revision by one other user not shown)
Line 4: Line 4:
 
[[Category: PM exposure health effects]]
 
[[Category: PM exposure health effects]]
  
−
'''Boxes with dashed borders''' contain brief guidance text for completing the entries for new variables.
 
  
 
== Scope ==
 
== Scope ==
  
−
This includes a verbal definition of the spatial, temporal, and other limits
+
 
−
(system boundaries) of the variable. The scope is defined according to the use
 
−
purpose of the assessment(s) that the variable belongs to.
 
  
 
Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.  
 
Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.  
Line 22: Line 19:
 
=== Data ===
 
=== Data ===
  
−
Description of the data used for obtaining the value of the variable
 
−
(e.g. measurement data; mathematical method and its parameters).
 
−
Please include references (preferably using the ''<nowiki><ref></ref></nowiki>'' tags)
 
−
and links to original data, as appropriate.
 
  
 
'''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref>
 
'''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref>
−
*RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by people with asthma per 10 µg/m<sup>3</sup> PM<sub>10</sub>
+
*RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m<sup>3</sup> PM<sub>10</sub>
−
**Note! the association is not statistically significant at the usual 5% level.
+
*RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m<sup>3</sup> PM<sub>10</sub>
 +
 
 +
Note! the associations are not statistically significant at the usual 5% level.
  
 
'''''CAFE CBA (2005)<ref>[http://ec.europa.eu/environment/archives/air/cafe/pdf/cba_methodology_vol2.pdf Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.]</ref>
 
'''''CAFE CBA (2005)<ref>[http://ec.europa.eu/environment/archives/air/cafe/pdf/cba_methodology_vol2.pdf Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.]</ref>
−
*change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> in children aged 5-14 years
+
*Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria)
 +
**Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use
 +
*Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> per 1000 adults aged 20+ with well-established asthma with asthma (well-established)
 +
**Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use
 +
**4.5% of European adult population was estimated to have well-established asthma
  
 
=== Causality ===
 
=== Causality ===
  
−
List of upstream variables.
 
−
The variables can be listed used descriptive (free-format) names or unambiguous identifiers
 
−
(e.g. [[Analytica]] IDs).
 
  
 
=== Unit ===
 
=== Unit ===
  
−
Unit in which the result is expressed.
 
  
−
Change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure
+
 
 +
Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons
  
 
=== Formula ===
 
=== Formula ===
  
−
Algebra or other explicit methods if possible
 
−
(e.g. [[Analytica]] code between the <nowiki>''<anacode></anacode>''</nowiki> delimiters).
 
  
 
== Result ==
 
== Result ==
  
−
If possible, a numerical expression or distribution.
+
 
  
 
{|{{prettytable}}
 
{|{{prettytable}}
Line 60: Line 54:
 
! 95% Cl
 
! 95% Cl
 
|-----
 
|-----
−
|  
+
| 5-14
−
|
+
| 180
−
|
+
| -690, 1060
 +
|-----
 +
| 20+
 +
| 912
 +
| -912, 2774
 +
|}
 
|}
 
|}
  
 
==See also==
 
==See also==
  
−
Links to relevant information that does not belong to ''Definition''.
+
 
  
 
*[http://www.needs-project.org/docs/results/RS1b/NEEDS_Rs1b_D3.7.pdf NEEDS - New Energy Externalities Developments for Sustainability, Deliverable 3.7 "A set of concentration-response function", Integrated Project, Sixth Framework Programme, Project no. 502687.]
 
*[http://www.needs-project.org/docs/results/RS1b/NEEDS_Rs1b_D3.7.pdf NEEDS - New Energy Externalities Developments for Sustainability, Deliverable 3.7 "A set of concentration-response function", Integrated Project, Sixth Framework Programme, Project no. 502687.]
Line 73: Line 72:
 
==References==
 
==References==
  
−
Will appear here automatically, if cited above using the ''<nowiki><ref></ref></nowiki>'' tags.
+
 
−
Additional references can also be listed here.
 
  
 
<references/>
 
<references/>

Latest revision as of 10:11, 18 November 2009


Scope

Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.

Dimensions and boundaries relevant for the variable

  • Age of exposed population
  • Country/other geographic area

Definition

Data

WHO task group (2004) [1]

  • RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m3 PM10
  • RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m3 PM10

Note! the associations are not statistically significant at the usual 5% level.

CAFE CBA (2005)[2]

  • Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m3 PM10 per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria)
    • Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use
  • Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m3 PM10 per 1000 adults aged 20+ with well-established asthma with asthma (well-established)
    • Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use
    • 4.5% of European adult population was estimated to have well-established asthma

Causality

Unit

Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons

Formula

Result

Age group Days 95% Cl
5-14 180 -690, 1060
20+ 912 -912, 2774

|}

See also

References

  1. ↑ Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.
  2. ↑ Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.
Retrieved from "http://www.opasnet.org/testiwiki/index.php?title=ERF_for_short_term_PM10_exposure_and_medication_usage_by_people_with_asthma&oldid=11969"